Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series

被引:87
作者
Klaire, Sukhpreet [1 ]
Zivanovic, Rebecca [2 ,3 ]
Barbic, Skye Pamela [2 ,4 ,5 ]
Sandhu, Raman [3 ]
Mathew, Nickie [3 ,6 ]
Azar, Pouya [2 ,3 ,7 ]
机构
[1] British Columbia Ctr Subst Use, Vancouver, BC, Canada
[2] Foundry Cent Off, Vancouver, BC, Canada
[3] Univ British Columbia, Vancouver, BC, Canada
[4] Univ British Columbia, Dept Occupat Sci & Occupat Therapy, Vancouver, BC, Canada
[5] St Pauls Hosp, Ctr Hlth Evaluat Outcome Sci, Vancouver, BC, Canada
[6] Surrey Mem Hosp, Surrey, BC, Canada
[7] Vancouver Gen Hosp, Complex Pain & Addict Serv, Vancouver, BC, Canada
关键词
ADDICTION;
D O I
10.1111/ajad.12869
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background and Objectives Buprenorphine/naloxone has been shown to be effective in the treatment of opioid use disorder. Due to its pharmacological properties, induction can be challenging, time-consuming, and result in sudden onset of withdrawal symptoms. Methods Retrospective case series (n = 2). Results Two patients with opioid use disorder were successfully started on buprenorphine/naloxone using a rapid micro-induction technique that did not cause precipitated withdrawal or require preceding cessation of other opioids. Discussion and Conclusions These cases provide an alternative method for starting buprenorphine/naloxone that offers unique benefits compared to protocols previously described in the literature. Scientific Significance This method can be used to minimize barriers to opioid agonist therapy. (Am J Addict 2019;28:262-265)
引用
收藏
页码:262 / 265
页数:4
相关论文
共 20 条
[1]  
[Anonymous], COCHRANE DATABASE SY
[2]  
British Columbia Centre on Substance Use, 2017, GUID CLIN MAN OP US
[3]   Management of opioid use disorders: a national clinical practice guideline [J].
Bruneau, Julie ;
Ahamad, Keith ;
Goyer, Marie-Eve ;
Poulin, Ginette ;
Selby, Peter ;
Fischer, Benedikt ;
Wild, T. Cameron ;
Wood, Evan .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2018, 190 (09) :E247-E257
[4]   Pharmacokinetics of the combination tablet of buprenorphine and naloxone [J].
Chiang, CN ;
Hawks, RL .
DRUG AND ALCOHOL DEPENDENCE, 2003, 70 :S39-S47
[5]   Fentanyl in the US heroin supply: A rapidly changing risk environment [J].
Ciccarone, Daniel .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2017, 46 :107-111
[6]   Relationship between Nonmedical Prescription-Opioid Use and Heroin Use [J].
Compton, Wilson M. ;
Jones, Christopher M. ;
Baldwin, Grant T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (02) :154-163
[7]  
Daitch J, 2012, PAIN PHYSICIAN, V15, pES59
[8]   Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers [J].
Greenwald, MK ;
Johanson, CE ;
Moody, DE ;
Woods, JH ;
Kilbourn, MR ;
Koeppe, RA ;
Schuster, CR ;
Zubieta, JK .
NEUROPSYCHOPHARMACOLOGY, 2003, 28 (11) :2000-2009
[9]   Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method [J].
Hammig, Robert ;
Kemter, Antje ;
Strasser, Johannes ;
von Bardeleben, Ulrich ;
Gugger, Barbara ;
Walter, Marc ;
Dursteler, Kenneth M. ;
Vogel, Marc .
SUBSTANCE ABUSE AND REHABILITATION, 2016, 7 :99-105
[10]   Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial [J].
Hser, Yih-Ing ;
Saxon, Andrew J. ;
Huang, David ;
Hasson, Al ;
Thomas, Christie ;
Hillhouse, Maureen ;
Jacobs, Petra ;
Teruya, Cheryl ;
McLaughlin, Paul ;
Wiest, Katharina ;
Cohen, Allan ;
Ling, Walter .
ADDICTION, 2014, 109 (01) :79-87